Prevention of host-to-host transmission by SARS-CoV-2 vaccines.
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
11
05
2021
revised:
09
07
2021
accepted:
28
07
2021
pubmed:
18
9
2021
medline:
5
2
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
As the number of individuals vaccinated against SARS-CoV-2 rises worldwide, population-level data regarding the vaccines' ability to reduce infection are being generated. Randomised trials have shown that these vaccines dramatically reduce symptomatic COVID-19; however, less is known about their effects on transmission between individuals. The natural course of infection with SARS-CoV-2 involves infection of the respiratory epithelia and replication within the mucosa to sufficient viral titres for transmission via aerosol particles and droplets. Here we discuss the available data on the existing, approved SARS-CoV-2 vaccines' capacity to reduce transmissibility by reducing primary infection, viral replication, capacity for transmission, and symptomaticity. The potential for mucosal-targeted SARS-CoV-2 vaccine strategies to more effectively limit transmission than intramuscular vaccines is considered with regard to known immunological mechanisms. Finally, we enumerate the population-level effects of approved vaccines on transmission through observational studies following clinical trials and vaccine distribution in real-world settings.
Identifiants
pubmed: 34534512
pii: S1473-3099(21)00472-2
doi: 10.1016/S1473-3099(21)00472-2
pmc: PMC8439617
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin A
0
Immunoglobulin G
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e52-e58Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests AI is an investigator of the Howard Hughes Medical Institute; serves as a paid consultant to 4BIO; and is a co-founder of RIGImmune. All other authors declare no competing interests.
Références
JAMA Intern Med. 2021 Oct 1;181(10):1343-1350
pubmed: 34424260
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
N Engl J Med. 2021 Jul 29;385(5):474-476
pubmed: 34010526
Elife. 2021 Apr 08;10:
pubmed: 33830018
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Ann N Y Acad Sci. 1998 May 1;840:586-90
pubmed: 9629285
JAMA. 2021 Jun 22;325(24):2500-2502
pubmed: 33956050
Annu Rev Immunol. 2016 May 20;34:575-608
pubmed: 27168245
N Engl J Med. 2021 Aug 19;385(8):759-760
pubmed: 34161702
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nature. 2012 Nov 15;491(7424):463-7
pubmed: 23075848
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283
pubmed: 33589829
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Cell. 2021 Mar 4;184(5):1188-1200.e19
pubmed: 33577765
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2021 Jul 6;326(1):35-45
pubmed: 34037666
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924
pubmed: 33332292
Science. 2022 Mar 11;375(6585):1151-1154
pubmed: 35084937
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 May 20;384(20):1962-1963
pubmed: 33755374
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Hum Vaccin Immunother. 2017 Jan 2;13(1):34-45
pubmed: 27936348
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1653-1656
pubmed: 33382675
PLoS Comput Biol. 2021 Mar 17;17(3):e1008785
pubmed: 33730053
Pathog Immun. 2021 Jun 7;6(1):116-134
pubmed: 34136730
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Sci Rep. 2021 Dec 27;11(1):24448
pubmed: 34961780
Clin Infect Dis. 2022 Jan 7;74(1):59-65
pubmed: 33704435
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):639-643
pubmed: 33914720
Open Forum Infect Dis. 2021 Jun 09;8(6):ofab262
pubmed: 34189176
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Cell. 2020 Oct 1;183(1):169-184.e13
pubmed: 32931734
J Infect. 2020 Sep;81(3):357-371
pubmed: 32615199
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379
pubmed: 33900384
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
PLoS One. 2020 Dec 9;15(12):e0243597
pubmed: 33296437
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nat Rev Immunol. 2018 Jan;18(1):46-61
pubmed: 29063907
Otolaryngol Head Neck Surg. 2021 Feb;164(2):305-307
pubmed: 33320052
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nat Med. 2021 May;27(5):892-903
pubmed: 33767405
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428